Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status

BACKGROUND: Patients with dedifferentiated or anaplastic thyroid carcinomas currently lack appropriate treatment options. Kinase inhibitors are among the most promising new agents as alternative strategies. The BRAF- and multi-kinase inhibitor, sorafenib, has already shown antitumor effects in thyro...

Descripción completa

Detalles Bibliográficos
Autores principales: Broecker-Preuss, Martina, Müller, Stefan, Britten, Martin, Worm, Karl, Schmid, Kurt Werner, Mann, Klaus, Fuhrer, Dagmar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377064/
https://www.ncbi.nlm.nih.gov/pubmed/25879531
http://dx.doi.org/10.1186/s12885-015-1186-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377064/
https://www.ncbi.nlm.nih.gov/pubmed/25879531
http://dx.doi.org/10.1186/s12885-015-1186-0

Ejemplares similares